Literature DB >> 24528803

Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.

Nobutoshi Komatsu1, Utaroh Motosugi, Shinya Maekawa, Kuniaki Shindo, Minoru Sakamoto, Mitsuaki Sato, Akihisa Tatsumi, Mika Miura, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Mitsuharu Fukasawa, Tomoyoshi Uetake, Masahiko Ohtaka, Tadashi Sato, Yasuhiro Asahina, Masayuki Kurosaki, Namiki Izumi, Tomoaki Ichikawa, Tsutomu Araki, Nobuyuki Enomoto.   

Abstract

AIM: To investigate whether the patients with hypovascular liver nodules determined on the arterial phase and hypointensity on the hepatocyte phase gadoxetic acid-enhanced magnetic resonance imaging (hypovascular hypointense nodules) are at increased risk of hepatocarcinogenesis, we assessed subsequent typical hepatocellular carcinoma (HCC) development at any sites of the liver with and without such nodules.
METHODS: One hundred and twenty-seven patients with chronic hepatitis B or C and without a history of HCC, including 68 with liver cirrhosis, were divided into those with (non-clean liver group, n = 18) and without (clean liver group, n = 109) hypovascular hypointense nodules. All the patients were followed up for 3 years, and HCC development rates and risk factors were analyzed with the Kaplan-Meier method and the Cox proportional hazard model, respectively.
RESULTS: A total of 17 patients (10 in the non-clean liver group and seven in the clean liver group) developed typical HCC. Cumulative 3-year rates of HCC development were 55.5% in the non-clean liver group and 6.4% in the clean liver group (P < 0.001), and those at the different sites from the initial nodules was also higher in the non-clean liver group (22.2%) than the clean liver group (6.4%) (P = 0.003). Multivariate analysis identified older age (P = 0.024), low platelet counts (P = 0.017) and a non-clean liver (P < 0.001) as independent risk factors for subsequent HCC development.
CONCLUSION: Patients with hypovascular hypointense liver nodules are at a higher risk for HCC development at any sites of the liver than those without such nodules.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  gadoxetic acid; hepatocellular carcinoma; hepatocyte phase; magnetic resonance imaging; risk assessment

Year:  2014        PMID: 24528803     DOI: 10.1111/hepr.12309

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 3.  Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 4.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

5.  Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.

Authors:  Chiara Briani; Marco Di Pietropaolo; Massimo Marignani; Francesco Carbonetti; Paola Begini; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2018-09

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma.

Authors:  Masanori Matsuda
Journal:  World J Hepatol       Date:  2015-12-28

8.  Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Tenyu Motoyama; Naoya Kanogawa; Tomoko Saito; Yusuke Shinozaki; Eiichiro Suzuki; Yoshihiko Ooka; Akinobu Tawada; Hideyuki Kato; Shinichiro Okabe; Fumihiko Kanai; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.